This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.
SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in BioMedWire editorial coverage examining the rapid growth of the GLP-1 market, with the company highlighted for its subsidiary GlucaPharm Inc. and its development of GEP-44, a patented triple agonist peptide licensed from Syracuse University. The editorial notes that GEP-44 is designed to target GLP-1 and peptide YY receptors Y1 and Y2, positioning SureNano as an emerging microcap participant seeking to address limitations of first-generation GLP-1 therapies, including efficacy, tolerability and delivery flexibility.
The coverage also places SureNano alongside established and emerging metabolic disease companies including Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT), underscoring accelerating momentum across the obesity, diabetes and cardiometabolic treatment landscape. BioMedWire notes SureNano’s broader platform strategy, including evaluation of oral, sublingual and intranasal delivery approaches, as well as early-stage opportunities involving formulation and delivery technologies that could expand the company’s long-term therapeutic scope.
To view the full press release, visit https://ibn.fm/2NGrw
About SureNano Science Ltd.
SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated February 23, 2026). The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.
NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN